Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coherus Oncology, Inc. (CHRS)

Coherus Oncology declares special CVR dividend tied to legacy biosimilar assets

Neutral Impact 3 of 5 shareholder Written later

Coherus Oncology declared a special dividend of contingent value rights (CVRs) to shareholders of record on September 30, 2026, with distribution on October 7, 2026. CVR holders may receive future cash payments only if the company sells or licenses its remaining biosimilar assets, and any payments depend on net cash proceeds actually received during a term ending October 7, 2028.

Key points

  • One CVR per common share held at 5:00 p.m. Eastern Time on September 30, 2026 (Record Date); distribution date October 7, 2026
  • Payments depend on net cash proceeds from the Legacy BioSim Assets, which include patents, royalties under an existing license, cell lines and related materials; no minimum payment is guaranteed
  • CVRs expire October 7, 2028 and are non-transferable and not listed; a Loan and Security Agreement dated August 12, 2026 with Innovatus Life Sciences Lending Fund I, L.P. restricts disposition of the assets and CVR payments

The filing

CompanyCoherus Oncology, Inc. (CHRS)
Form8-K, current report
Filed with the SECAug 17, 2026, 5:28 PM ET
Accession number0001104659-26-097951

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.